ATE401340T1 - Verfahren zur verbesserung der proteinkonformation mit hilfe von reduktionsmitteln - Google Patents

Verfahren zur verbesserung der proteinkonformation mit hilfe von reduktionsmitteln

Info

Publication number: ATE401340T1
Authority: AT; Austria
Prior art keywords: recombinant protein; purification; protein; conformity; recombinant
Prior art date: 1998-04-17

Application number

AT04103238T

Other languages

English (en)

Inventor

Geert Maertens

Joost Louwagie

Alfons Bosman

Erwin Sablon

Maan Zrein

Original Assignee

Innogenetics Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-17

Filing date

1999-04-15

Publication date

2008-08-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8237028&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE401340(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-04-15 Application filed by Innogenetics Nv filed Critical Innogenetics Nv

2008-08-15 Application granted granted Critical

2008-08-15 Publication of ATE401340T1 publication Critical patent/ATE401340T1/de

Links

238000000034 method Methods 0.000 title abstract 2
102000004169 proteins and genes Human genes 0.000 title abstract 2
108090000623 proteins and genes Proteins 0.000 title abstract 2
239000003638 chemical reducing agent Substances 0.000 title 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 5
108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 5
238000000746 purification Methods 0.000 abstract 3
238000004587 chromatography analysis Methods 0.000 abstract 2
239000003599 detergent Substances 0.000 abstract 2
239000013592 cell lysate Substances 0.000 abstract 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
235000018417 cysteine Nutrition 0.000 abstract 1
230000009089 cytolysis Effects 0.000 abstract 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 abstract 1
239000006166 lysate Substances 0.000 abstract 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
- C12Q1/706—Specific hybridization probes for hepatitis
- C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54393—Improving reaction conditions or stability, e.g. by coating or irradiation of surface, by reduction of non-specific binding, by promotion of specific binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5767—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis non-A, non-B hepatitis
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Biochemistry (AREA)
Organic Chemistry (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Pathology (AREA)
Cell Biology (AREA)
Communicable Diseases (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Chemical Kinetics & Catalysis (AREA)
Virology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Bioinformatics & Cheminformatics (AREA)
General Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Gastroenterology & Hepatology (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Peptides Or Proteins (AREA)

AT04103238T 1998-04-17 1999-04-15 Verfahren zur verbesserung der proteinkonformation mit hilfe von reduktionsmitteln ATE401340T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP98870087		1998-04-17

Publications (1)

Publication Number	Publication Date
ATE401340T1 true ATE401340T1 (de)	2008-08-15

Family

ID=8237028

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT99920678T ATE278960T1 (de)	1998-04-17	1999-04-15	Verbessertes immundiagnostische tests durch verwendung von reduzierende agenzien
AT04103238T ATE401340T1 (de)	1998-04-17	1999-04-15	Verfahren zur verbesserung der proteinkonformation mit hilfe von reduktionsmitteln

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT99920678T ATE278960T1 (de)	1998-04-17	1999-04-15	Verbessertes immundiagnostische tests durch verwendung von reduzierende agenzien

Country Status (21)

Country	Link
US (1)	US7935490B2 (de)
EP (2)	EP1471074B1 (de)
JP (2)	JP2002512370A (de)
KR (1)	KR20010042807A (de)
CN (1)	CN1305589A (de)
AT (2)	ATE278960T1 (de)
AU (1)	AU751362B2 (de)
BR (1)	BRPI9909678B8 (de)
CA (2)	CA2658218C (de)
CY (1)	CY1108424T1 (de)
CZ (1)	CZ298268B6 (de)
DE (2)	DE69939132D1 (de)
DK (2)	DK1071955T4 (de)
ES (2)	ES2310701T3 (de)
HU (1)	HUP0101719A3 (de)
IL (1)	IL138791A0 (de)
PL (1)	PL343469A1 (de)
PT (2)	PT1071955E (de)
TR (4)	TR200101647T2 (de)
WO (1)	WO1999054735A1 (de)
ZA (1)	ZA200005445B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU765940B2 (en) *	1998-06-24	2003-10-02	Innogenetics N.V.	Particles of HCV envelope proteins: use for vaccination
JP5175417B2 (ja) *	2000-08-17	2013-04-03	トリペップアクチボラゲット	リバビリンを含むワクチンおよびその使用方法
US7022830B2 (en)	2000-08-17	2006-04-04	Tripep Ab	Hepatitis C virus codon optimized non-structural NS3/4A fusion gene
CN1636050A (zh) *	2001-04-24	2005-07-06	基因创新有限公司	核心糖基化hcv包膜蛋白
JP2004108914A (ja) *	2002-09-18	2004-04-08	Kudo Norio	コラーゲンの測定方法
AU2003283365A1 (en) *	2002-11-08	2004-06-07	Innogenetics N.V.	HCV vaccine compositions comprising E1 and NS3 peptides
US20050014136A1 (en) *	2003-05-28	2005-01-20	Innogenetics N.V.	Modified HCV NS5
CA2544185C (en) *	2003-10-28	2010-09-28	Advanced Life Science Institute, Inc.	Method of detecting hepatitis c virus
JP2009543099A (ja) *	2006-07-07	2009-12-03	ポール・コーポレーション	親和性捕捉中の変性剤の使用
US20100304353A1 (en) *	2007-07-16	2010-12-02	Pfizer Inc	Methods of improving a genomic marker index of dairy animals and products
US20110123983A1 (en) *	2007-09-12	2011-05-26	Pfizer Inc.	Methods of Using Genetic Markers and Related Epistatic Interactions
BRPI0818300A2 (pt) *	2007-10-03	2017-05-09	Pfizer	marcadores genéticos para gado com chifres e sem chifres e processos relacionados
WO2009085689A2 (en) *	2007-12-17	2009-07-09	Pfizer Inc.	Methods of improving genetic profiles of dairy animals and products
CN102089662B (zh) *	2008-07-16	2015-05-27	雷迪奥米特医学公司	高容量固相
CN102081018A (zh) *	2009-11-30	2011-06-01	希森美康株式会社	样品的预处理方法及hcv的免疫测定方法
FR2984328B1 (fr)	2011-12-20	2016-12-30	Bio-Rad Innovations	Procede de detection d'une infection par le virus de l'hepatite c
ES2828713T3 (es)	2014-10-29	2021-05-27	Abbott Lab	Ensayos de detección de anticuerpos anti-VHC objeto usando péptidos de captura NS3
CN109870581B (zh) *	2017-12-04	2021-05-04	厦门万泰凯瑞生物技术有限公司	一种定量检测HBsAg的试剂盒及方法
CN109678954B (zh) *	2018-12-29	2022-01-07	山东莱博生物科技有限公司	一对能够特异性识别hcv ns3蛋白的单克隆抗体及其应用
CN110988362B (zh) *	2019-12-20	2023-11-14	迈克生物股份有限公司	抗组蛋白抗体测定试剂、试剂盒及其使用方法
CN112225783B (zh) *	2020-09-16	2021-08-31	东莞市朋志生物科技有限公司	Hcv重组抗原及其突变体
CN112285361B (zh) *	2020-09-27	2023-12-05	中国人民解放军空军军医大学	排除抗-cd38单克隆抗体药物对抗人球蛋白检测干扰的试剂
CN113219169B (zh) *	2021-05-22	2021-12-17	北京金诺百泰生物技术有限公司	生物检测用封闭剂及其制备方法、包被板及应用该包被板的试剂盒
CN115112897B (zh) *	2021-12-10	2024-11-01	中山大学附属第八医院（深圳福田）	一种用于鉴别抗体检测生物学假阳性的方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0139526A2 (de) *	1983-10-20	1985-05-02	Warner-Lambert Company	Unlöslich gemachtes stabiles spezifisches Bindungsprotein
US4616078A (en) *	1985-04-08	1986-10-07	Eli Lilly And Company	Process for purifying proinsulin-like materials
CA1340877C (en) *	1987-12-28	2000-01-18	Takashi Sugiyama	Elastase inhibitory polypeptide and process for production thereof by recombinant gene technology
ATE92633T1 (de) *	1988-05-11	1993-08-15	Abbott Lab	Verfahren zur erhoehung der spezifizitaet in kompetitiven immuntests.
US4923967A (en) *	1988-09-26	1990-05-08	Eli Lilly And Company	Purification and refolding of recombinant proteins
US6194140B1 (en) *	1990-04-04	2001-02-27	Chiron Corporation	HCV NS3 protein fragments having helicase activity and improved solubility
DE69133402T2 (de) *	1990-04-04	2004-11-11	Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville	Protease von hepatitis-c-virus
US5606031A (en) *	1990-04-06	1997-02-25	Lile; Jack	Production and purification of biologically active recombinant neurotrophic protein in bacteria
ES2188583T3 (es) *	1991-06-24	2003-07-01	Chiron Corp	Polipeptidos para el virus de la hepatitis c (hcv).
JP3225468B2 (ja)	1992-08-28	2001-11-05	ダイナボット株式会社	抗体測定用試薬
EP0984068B1 (de)	1993-04-27	2012-03-28	Innogenetics N.V.	Sequenzen von Hepatitis C Virus-Genotypen sowie ihre Verwendungen als Therapeutika und Diagnostika
ATE236981T1 (de)	1993-11-04	2003-04-15	Innogenetics Nv	Von menschlichen t-zellen immunodominante epiropen des virus der c-hepatitis
JPH10503274A (ja)	1994-06-23	1998-03-24	エナジーアンスワーズコーポレーション	廃棄物から灰製品およびエネルギーを生成するシステム
ES2174957T5 (es) *	1994-07-29	2006-12-16	Innogenetics N.V.	Proteinas purificadas de envoltura de virus de la hepatitis c para uso diagnostico y terapeutico.
DE4428705A1 (de) *	1994-08-12	1996-02-15	Boehringer Mannheim Gmbh	Rekombinantes Antigen aus der NS3-Region des Hepatitis C Virus
JPH0862219A (ja)	1994-08-19	1996-03-08	Dainabotsuto Kk	還元型抗原に対する抗体アッセイ試薬及びそれを使用した測定方法
JPH10507643A (ja)	1994-10-21	1998-07-28	イノジェネティックス・ナムローゼ・フェンノートシャップ	Ｃ型肝炎ウイルス遺伝子型の新規配列、ならびにそれらの予防薬、治療薬および診断薬としての使用
US5705330A (en)	1995-04-14	1998-01-06	Abbott Laboratories	Chemiluminescent immunoassay for antibody detection
US5616460A (en)	1995-06-07	1997-04-01	Abbott Laboratories	Buffer composition for reagents for immunoassay
NZ333431A (en)	1996-05-24	2000-05-26	Chiron Corp	Multiple epitope fusion protein selected from HIV or HCV, method of immunoassay and assay device
EP0984846B1 (de) *	1997-01-13	2004-11-24	Rodel, Inc.	Verfahren zum herstellen von einem photolithographisch gemusterten kunststoffpolierkissen

1999
- 1999-04-15 DK DK99920678T patent/DK1071955T4/da active
- 1999-04-15 AT AT99920678T patent/ATE278960T1/de active
- 1999-04-15 DK DK04103238T patent/DK1471074T3/da active
- 1999-04-15 BR BRPI9909678A patent/BRPI9909678B8/pt not_active IP Right Cessation
- 1999-04-15 AU AU38171/99A patent/AU751362B2/en not_active Expired
- 1999-04-15 TR TR2001/01647T patent/TR200101647T2/xx unknown
- 1999-04-15 IL IL13879199A patent/IL138791A0/xx unknown
- 1999-04-15 CA CA2658218A patent/CA2658218C/en not_active Expired - Lifetime
- 1999-04-15 ES ES04103238T patent/ES2310701T3/es not_active Expired - Lifetime
- 1999-04-15 CZ CZ20003819A patent/CZ298268B6/cs not_active IP Right Cessation
- 1999-04-15 TR TR2002/02213T patent/TR200202213T2/xx unknown
- 1999-04-15 HU HU0101719A patent/HUP0101719A3/hu unknown
- 1999-04-15 JP JP2000545027A patent/JP2002512370A/ja active Pending
- 1999-04-15 PT PT99920678T patent/PT1071955E/pt unknown
- 1999-04-15 DE DE69939132T patent/DE69939132D1/de not_active Expired - Lifetime
- 1999-04-15 WO PCT/EP1999/002547 patent/WO1999054735A1/en not_active Ceased
- 1999-04-15 CA CA002324970A patent/CA2324970C/en not_active Expired - Lifetime
- 1999-04-15 EP EP04103238A patent/EP1471074B1/de not_active Expired - Lifetime
- 1999-04-15 DE DE69920895T patent/DE69920895T3/de not_active Expired - Lifetime
- 1999-04-15 PL PL99343469A patent/PL343469A1/xx unknown
- 1999-04-15 AT AT04103238T patent/ATE401340T1/de active
- 1999-04-15 CN CN99807283A patent/CN1305589A/zh active Pending
- 1999-04-15 TR TR2001/01648T patent/TR200101648T2/xx unknown
- 1999-04-15 TR TR2000/03024T patent/TR200003024T2/xx unknown
- 1999-04-15 EP EP99920678A patent/EP1071955B2/de not_active Expired - Lifetime
- 1999-04-15 ES ES99920678T patent/ES2230851T5/es not_active Expired - Lifetime
- 1999-04-15 PT PT04103238T patent/PT1471074E/pt unknown
- 1999-04-15 KR KR1020007011555A patent/KR20010042807A/ko not_active Ceased
2000
- 2000-10-05 ZA ZA200005445A patent/ZA200005445B/en unknown
2005
- 2005-01-05 JP JP2005000767A patent/JP3974620B2/ja not_active Expired - Lifetime
2006
- 2006-08-02 US US11/497,259 patent/US7935490B2/en not_active Expired - Fee Related
2008
- 2008-10-16 CY CY20081101157T patent/CY1108424T1/el unknown

Also Published As

Publication number	Publication date
CA2658218C (en)	2014-10-28
BRPI9909678B8 (pt)	2021-05-25
PL343469A1 (en)	2001-08-13
CA2324970C (en)	2009-06-30
PT1071955E (pt)	2005-02-28
DE69920895T2 (de)	2005-10-13
PT1471074E (pt)	2008-10-23
TR200202213T2 (tr)	2002-11-21
TR200101647T2 (tr)	2002-06-21
AU3817199A (en)	1999-11-08
AU751362B2 (en)	2002-08-15
TR200003024T2 (tr)	2000-12-21
HK1036653A1 (en)	2002-01-11
DK1071955T4 (da)	2009-06-15
EP1471074B1 (de)	2008-07-16
CY1108424T1 (el)	2014-04-09
JP2005185285A (ja)	2005-07-14
CZ20003819A3 (cs)	2001-10-17
EP1071955A1 (de)	2001-01-31
ZA200005445B (en)	2003-01-06
EP1471074A3 (de)	2004-11-10
IL138791A0 (en)	2001-10-31
DE69939132D1 (de)	2008-08-28
JP3974620B2 (ja)	2007-09-12
TR200101648T2 (tr)	2002-06-21
CN1305589A (zh)	2001-07-25
CA2658218A1 (en)	1999-10-28
US7935490B2 (en)	2011-05-03
DE69920895T3 (de)	2009-09-03
DK1471074T3 (da)	2008-11-17
JP2002512370A (ja)	2002-04-23
CZ298268B6 (cs)	2007-08-08
EP1471074A2 (de)	2004-10-27
EP1071955B2 (de)	2009-02-18
HUP0101719A3 (en)	2006-05-29
BR9909678B1 (pt)	2013-11-12
ES2230851T5 (es)	2009-06-25
US20060263854A1 (en)	2006-11-23
DE69920895D1 (de)	2004-11-11
DK1071955T3 (da)	2005-02-07
ES2310701T3 (es)	2009-01-16
EP1071955B1 (de)	2004-10-06
KR20010042807A (ko)	2001-05-25
CA2324970A1 (en)	1999-10-28
HUP0101719A2 (hu)	2001-09-28
WO1999054735A1 (en)	1999-10-28
ES2230851T3 (es)	2005-05-01
ATE278960T1 (de)	2004-10-15
BR9909678A (pt)	2000-12-19

Legal Events

Date

Code

Title

Description

2009-02-15

UEP

Publication of translation of european patent specification

Ref document number: 1471074

Country of ref document: EP

Publication	Publication Date	Title
ATE401340T1 (de)	2008-08-15	Verfahren zur verbesserung der proteinkonformation mit hilfe von reduktionsmitteln
DE69711034D1 (de)	2002-04-18	Wässrige fluorpolymerlösungen zur behandlung von harten oberflächen
DK1075488T4 (da)	2013-10-21	Proteinoprensning ved ionbytningskromatografi
DE69412828D1 (de)	1998-10-01	Zusammensetzung zur benetzung von kontaktlinsen
WO2004024866A3 (en)	2004-10-14	Protein purification
DE69409457D1 (de)	1998-05-14	Mittel zur Entfernung von Photoresist, das zur Verminderung von Metallkorrosion reduzierende Stoffe enthält
DE69812773D1 (de)	2003-05-08	Methode zur de novo Peptidsequenz-Bestimmung
DK0495918T3 (da)	1996-02-19	Aminosyre-beta-lyaseenzyminhibitorer som deodoranter
ATE185146T1 (de)	1999-10-15	Verfahren zur entfernung von n-terminalem methionin
EP1038371A4 (de)	2002-01-30	Unwandlungsverfahren zur optimierung von kryptographischen berechnungen über elliptische kurven
DE69720335D1 (de)	2003-05-08	Recombinante Fructosyl-Aminosäure-Oxidase
DE3683987D1 (de)	1992-04-02	Methode zur reinigung von alkoxysilanen.
NO971508L (no)	1997-06-13	Analoger av sur fibroblastvekstfaktor med forökt stabilitet og biologisk aktivitet
ATE224725T1 (de)	2002-10-15	Stabilisierung von interferonen in wässriger lösung durch gummiarabikum
DE68907143D1 (de)	1993-07-22	Verfahren zur reinigung von kohlenstofffluoriden.
NO2006006I1 (no)	2006-05-15	Aktivert protein C
DE3670482D1 (de)	1990-05-23	Katalystisches reduzierungsverfahren zur produktion von aromatischen aminoverbindungen.
FI963755A7 (fi)	1996-09-20	Glutamaatti-dekarboksylaasi-aktiivisuutta (GAD-aktiivisuutta) koodaava t yhdistelmä-DNA-tekniset virukset
DE69734708D1 (de)	2005-12-29	Kristallisation eines proteins mit einem schwefelsalz
ATE199556T1 (de)	2001-03-15	Verfahren zur fraktionierung von deacylierten glycerophospholipiden
DE69721065D1 (de)	2003-05-22	Verfahren zur reiningung von 1,3,5-triisopropylbenzol
DE59909959D1 (de)	2004-08-19	Verfahren zur aufreinigung von (+-)2-azabicyclo (2.2.1)hept-5-en-3-on
ATE318308T1 (de)	2006-03-15	Stabilisierung von dobbelsträngigen nukleinsäuren mit proteinen